Sanofi Company Description
Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally.
It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products.
It also supplies poliomyelitis, pertussis, and hib pediatric vaccines; and influenza, adult booster, meningitis, and travel and endemic vaccines.
In addition, the company offers allergy, cough and cold, pain, liver care, physical and mental wellness, probiotics, digestive, and nutritional products; and other products, such as daily body lotions, anti-itch products, moisturizing and soothing lotions, and body and foot creams, as well as powders for eczema.
Further, it has various pharmaceutical products and vaccines in development stage. Sanofi has collaboration agreement with GlaxoSmithKline to develop a recombinant Covid-19 vaccine; and a research collaboration with Stanford University School of Medicine to advance the understanding of immunology and inflammation through open scientific exchange.
It also has a collaboration and license option agreement with Prellis Biologics, Inc. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011.
Sanofi was founded in 1973 and is headquartered in Paris, France.
| Country | United States |
| Founded | 1994 |
| Industry | Drug Manufacturers - General |
| Sector | Healthcare |
| Employees | 82,878 |
| CEO | Paul Hudson |
Contact Details
Address: 46, avenue de la Grande Armée, Paris France | |
| Phone | 33 1 53 77 40 00 |
Stock Details
| Ticker Symbol | SNYNF |
| Exchange | OTCMKTS |
| Fiscal Year | January - December |
| Reporting Currency | EUR |
| ISIN Number | FR0000120578 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Paul Hudson | Chief Executive Officer and Director |
| François-Xavier Roger | Executive Vice President and Chief Financial Officer |
| Madeleine Roach | Executive Vice President and Head of Business Operations |
| Laurent Gilhodes | Principal Accounting Officer and Vice President of Corporate Accounting |
| Dr. Josephine Fubara | Chief Science Officer of Consumer Health Care |
| Thomas Kudsk Larsen | Head of Investor Relations |
| Dante Beccaria | Global Compliance Officer and Vice President |
| Roy Papatheodorou | Executive Vice President and General Counsel |
| Josep Catlla | Head of Communications |
| Pierre Chancel | Senior Vice President of Global Diabetes and Senior Vice President of Global Marketing |